Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb
Ten months after Novavax shares $NVAX were routed by the failure of its RSV F vaccine in Phase III in older subjects, the biotech is looking for a do-over. And the executive crew is trying to make a case that it can succeed where before it failed badly.
The company cobbled together topline claims on safety and immunogenicity data from a Phase II trial, some post hoc analysis from other studies, an assertion that an adjuvant approach would work better, and plans for a new mid-stage study to launch in older patients next year as it built its case that it knows now how to move ahead with a new development plan that can succeed in the wake of a nasty flop.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
